Naseem Zojwalla to Transform Patient Care as Olema Oncologys NewCMO
healthcaretechoutlook

Naseem Zojwalla to Transform Patient Care as Olema Oncologys NewCMO

Healthcare Tech Outlook | Friday, February 18, 2022

Dr. Zojwalla joins Olema Oncology as its chief medical officer with a wealth of experience in clinical development and regulatory strategy for innovative oncology medicines

Fremont, CA: “Naseem's comprehensive and nuanced understanding of what it takes to guide life-changing cancer medicines through various stages of clinical development will be instrumental as we continue to investigate the full potential of Olema’s science to improve outcomes for women living with cancer,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. Naseem Zojwalla, M.D., has been designated Chief Medical Officer of Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted treatments for women's cancers.

 "We are excited to welcome Naseem to the executive leadership team at this important time for Olema. Her passion, dedication and leadership will be integral in our journey to transform the standard of care for patients." adds Sean.

Dr. Zojwalla joins Olema as the company prepares to advance its lead therapeutic candidate, OP-1250, an investigational complete oestrogen receptor (ER) antagonist (CERAN) and a selective oestrogen receptor degrader (SERD) in development for the treatment of metastatic breast cancer, into Phase 2 development.

Dr. Zojwalla has previously held leadership positions in clinical development and strategy at biopharmaceutical companies such as Turning Point Therapeutics and Peloton Therapeutics (acquired by Merck & Co. Inc.), as well as clinical leadership positions at Onyx Pharmaceuticals, ImClone Systems, and Eisai Inc. She offers substantial experience in establishing world-class clinical development, operations, and pharmacovigilance teams to support increasing programs, as well as developing clinical assets from Phase 1 to registrational studies and regulatory experience with US and European authorities. She graduated from Temple University School of Medicine and went on to Columbia University Medical Center for her hematology/oncology fellowship.

Weekly Brief